Your browser doesn't support javascript.
loading
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
Kinstrie, Ross; Horne, Gillian A; Morrison, Heather; Irvine, David; Munje, Chinmay; Castañeda, Eduardo Gómez; Moka, Hothri A; Dunn, Karen; Cassels, Jennifer E; Parry, Narissa; Clarke, Cassie J; Scott, Mary T; Clark, Richard E; Holyoake, Tessa L; Wheadon, Helen; Copland, Mhairi.
Afiliação
  • Kinstrie R; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Horne GA; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Morrison H; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Irvine D; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Munje C; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Castañeda EG; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Moka HA; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Dunn K; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Cassels JE; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Parry N; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Clarke CJ; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Scott MT; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Clark RE; Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Holyoake TL; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Wheadon H; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Copland M; Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. Mhairi.Copland@glasgow.ac.uk.
Leukemia ; 34(6): 1613-1625, 2020 06.
Article em En | MEDLINE | ID: mdl-31896780
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Glicoproteínas de Membrana / Receptores de Complemento / Leucemia Mielogênica Crônica BCR-ABL Positiva / Biomarcadores Tumorais / Resistencia a Medicamentos Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Glicoproteínas de Membrana / Receptores de Complemento / Leucemia Mielogênica Crônica BCR-ABL Positiva / Biomarcadores Tumorais / Resistencia a Medicamentos Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article